Abstracts tagged "Comorbidity"

Abstract Number: 2759 • 2016 ACR/ARHP Annual Meeting
Prevalence of Comorbidities and Risk Factors of Spondyloarthritis in Latin America: A Comparative Study with the General Population: Data from the Multinational ASAS-Comospa Study
WILSON BAUTISTA-MOLANO^1,2, Robert Landewé³, Anna Molto⁴, Rubén Burgos-Vargas⁵, José Antonio Maldonado-Cocco⁶, Rafael Valle-Oñate⁷ and Désirée van der Heijde⁸, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology Department, School of Medicine, UMNG / HMC, Bogotá, Colombia, ³Amsterdam Medical Center, Amsterdam, Netherlands, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Rheumatology, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Rheumatology Department, School of Medicine, UMNG / HMC, Bogota, Colombia, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Increased risk of several comorbidities has been reported in spondyloarthritis (SpA). Data and knowledge regarding the prevalence of these comorbidities and risk factors in…
Abstract Number: 111 • 2016 ACR/ARHP Annual Meeting
Influences of Osteoarthritis Pain, Comorbid Insomnia, and Depression on Health Care Use in Older Adults with Osteoarthritis
Minhui Liu¹, Susan M. McCurry¹, Michael V. Vitiello², Basia Belza¹ and Michael Von Korff³, ¹University of Washington School of Nursing, Seattle, WA, ²Psychiatry and Behavioral Sciences, Biobehavioral Nursing and Health Systems, University of Washington School of Medicine, Seattle, WA, ³Group Health Research Institute, Seattle, WA
Background/Purpose: Osteoarthritis (OA), the most common type of arthritis, is prevalent and costly. Pain is the principal reason patients with OA seek treatment. Older adults…
Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Martin Aringer³, Guido Hoese⁴, Wolfgang Ochs⁵, Katja Thiele¹ and Angela Zink^1,2, ¹Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ⁴Rheumatologische Fachpraxis Stadthagen, Stadthagen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany
Background/Purpose: Methods: Conclusion:
Abstract Number: 909 • 2016 ACR/ARHP Annual Meeting
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Bhaskar Dasgupta¹, Asad Khan¹, Dimos Merinopoulos¹, Siwalik Banerjee², Dawn Gayford³, Philip Stapleton¹, Faidra Laskou¹ and Gianina Statache¹, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Wescliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital NHS Foundation Trust, westcliff-on-Sea, United Kingdom
Background/Purpose: It is reported that 15-25% patients with GCA present with visual complications. Sight loss (SL) in the elderly is associated with considerable morbidity. There…
Abstract Number: 1231 • 2016 ACR/ARHP Annual Meeting
Impact of Comorbidity on Health-Related Quality of Life and Healthcare Expenditure in Patients with Rheumatoid Arthritis
Eric Nyarko¹ and J An², ¹College of Pharmacy, Western University of Health Sciences, Pomona, CA, ²Western University of Health Sciences, Pomona, CA
Background/Purpose: Rheumatoid Arthritis (RA) is known to be associated with an increased risk of comorbidity, premature mortality, and disability. We investigated the effect of comorbidity…
Abstract Number: 1235 • 2016 ACR/ARHP Annual Meeting
Healthcare Utilization and Multimorbidities Among Adult Patients with Juvenile Idiopathic Arthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler⁷, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁶Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Active juvenile idiopathic arthritis (JIA) is commonly associated with high healthcare costs in children. The disabling consequences and multimorbidities often manifest, however, in adulthood.…
Abstract Number: 1480 • 2016 ACR/ARHP Annual Meeting
Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients
Samina A. Turk¹, Dirkjan van Schaardenburg^1,2, Willem F. Lems^1,3 and Mike T. Nurmohamed^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality. This cardiovascular risk is mainly determined by the lipid profile, which may change…
Abstract Number: 1552 • 2016 ACR/ARHP Annual Meeting
The Association of Fatigue, Comorbidities and Anti Rheumatic Drugs in Rheumatoid Arthritis: Results from French Cohort Study of Comorbidities
Anne Tournadre¹, Bruno Pereira², Laure Gossec³, Martin Soubrier⁴ and Maxime Dougados⁵, ¹Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Gabriel Montpied, Clermont-Ferrand, France, ³Sorbonne Universités, UPMC University Paris 06, Paris, France, Paris, France, ⁴Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Paris-Descartes University, Paris, France
Background/Purpose: The mechanisms of fatigue in rheumatoid arthritis (RA) are still unclear and the effect of antirheumatic drugs on fatigue not fully established. Objectives: To…
Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Jeffrey D. Greenberg², Leslie Harrold³ and J. Lynn Palmer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Southborough, MA, ³Department of Medicine, UMass Memorial Medical Center, Worcester, MA, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…
Abstract Number: 1418 • 2015 ACR/ARHP Annual Meeting
The Importance of Comorbidity in Understanding the 6-Month Trajectories of Pain and Function after Total Hip Arthroplasty
C. Allyson Jones¹, Gian S. Jhangri², Lauren A. Beaupre¹ and Maria E. Suarez-Almazor³, ¹Physical Therapy, University of Alberta, Edmonton, AB, Canada, ²School of Public Health, University of Alberta, Edmonton, AB, Canada, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Osteoarthritis (OA) is chronic condition associated with a number of other comorbidities which may affect the 6 month pattern of recovery of total hip…
Abstract Number: 1503 • 2015 ACR/ARHP Annual Meeting
A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Claire I. Daien¹, Amandine Tubery², Guilhem du Cailar³, Aurore Royanez⁴, Thibault Mura⁵, Marie-Christine Picot⁶, Rodolphe Bourret⁷, François Roubille⁸, Jean Bousquet⁹, Jacques Morel¹, Pierre Fesler³ and Bernard Combe¹⁰, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Nîmes University Hospital, Rheumatology Department, Nimes, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology and Pharmacology, Montpellier, France, ⁵CIC, Hopital Gui De Chauliac, Montpellier, France, ⁶DIM, Montpellier, France, ⁷Direction Teaching hospital, Montpellier, France, ⁸Cardiology, Montpellier, France, ⁹Pneumology, Montpellier, France, ¹⁰Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Patients with inflammatory rheumatisms especially rheumatoid arthritis (RA) have a greater risk of cardiovascular diseases (CVD), infections, chronic respiratory diseases (CRD) and osteoporosis. As…
Abstract Number: 2163 • 2015 ACR/ARHP Annual Meeting
Associations Between Sex Differences, Pain, Insomnia, and Depression in Older Adults with Osteoarthritis: A Cross-Sectional Study
Minhui Liu¹, Susan McCurry¹, Michael Vitiello², Basia Belza¹ and Michael Von Korff³, ¹University of Washington School of Nursing, Seattle, WA, ²Psychiatry and Behavioral Sciences, Biobehavioral Nursing and Health Systems, University of Washington School of Medicine, Seattle, WA, ³Group Health Research Institute, Seattle, WA
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis and affects nearly 30 million Americans. Chronic pain is the major symptom in OA and…
Abstract Number: 2878 • 2015 ACR/ARHP Annual Meeting
Treating Axial Spondyloarthritis to Target: Influence of the Population Characteristics and Comorbidities in Reaching Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Tnfalpha Inhibitors Agents
Sara Monti, Veronica Codullo, Vittorio Grosso, Silvia Breda, Carlomaurizio Montecucco and Roberto Caporali, Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy
Background/Purpose: The treat to target strategy (T2T), aiming at inactive disease (ID), has become the recommended approach also in the field of axial-SpA (axSpA) (1). …
Abstract Number: 3086 • 2015 ACR/ARHP Annual Meeting
The Same Multidimensional Patient Health Assessment Questionnaire Used to Assess RAPID3 in Rheumatoid Arthritis, Osteoarthritis and Other Rheumatic Diseases Can Provide Quantitative Clues to Recognize and Document Comorbid Fibromyalgia
Kathryn A. Gibson¹, Annie Huang² and Theodore Pincus², ¹Liverpool Hospital, Liverpool, Australia, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: An MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) is a 2 sided, 1 page questionnaire which is completed by patients in…
Abstract Number: 3119 • 2015 ACR/ARHP Annual Meeting
The Risk of Venous Thromboembolism in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Alexis Ogdie-Beatty¹, Daniel Shin², Junko Takeshita², Zelma ChiesaFuxench² and Joel Gelfand³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Health System , Philadelphia, PA
Background/Purpose: Venous thromboembolism (VTE), the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially deadly medical problem with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].